Related Experiment Video
Updated: Feb 5, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
Fungal-derived xenobiotic exhibits antibacterial and antibiofilm activity against Staphylococcus aureus
Siddhartha Kumar1, Arvind Kumar1, Manisha Kaushal2
1Department of Biotechnology, Central University of South Bihar.
Abstract:
Staphylococcus aureus is an opportunistic pathogen, responsible for superficial and invasive infections both in nosocomial and community-acquired settings. The incidences of infection have become more problematic attributable to emerging drug resistance and biofilm formation. These challenges suggest the need for new antimicrobial agents against S. aureus. In present work, we purified a fungal xenobiotic (FI3) which elicits a potent antimicrobial activity against a list of tested microbes including methicillin sensitive (MSSA) and methicillin resistance (MRSA) S. aureus. The cell growth of MSSA and MRSA were completely ceased with the 1× minimum inhibitory concentration (MIC); 32 µg/mL and 128 µg/mL, respectively. The cell viability severely decreased within 90 min, due to disturbance of membrane homeostasis. This bactericidal effect was enhanced at lower pH (pH 4) with a speculation to retain positive charge. The FI3 potently disrupts biofilm adherence at 64 µg/mL and found to be a safe with no toxic effect on mammalian tissue. FI3 also leads to increase the potency of tested antibiotics. Taken together, we established that FI3 has a potent antimicrobial activity against tested microbes and safer to human tissue. It may be proven a leading molecule for the treatment of bacterial infections.
Insights
A novel fungal compound, FI3, shows strong antimicrobial activity against Staphylococcus aureus, including drug-resistant strains. This safe compound effectively inhibits bacterial growth and biofilm formation, offering a promising new treatment option.
Area of Science:
- Microbiology
- Drug Discovery
- Biochemistry
Background:
- Staphylococcus aureus is a significant pathogen causing various infections.
- Increasing antibiotic resistance and biofilm formation in S. aureus necessitate novel antimicrobial strategies.
- Current treatments face challenges due to emerging drug resistance and biofilm formation.
Purpose of the Study:
- To identify and characterize a novel antimicrobial agent against Staphylococcus aureus.
- To evaluate the efficacy of the purified fungal xenobiotic (FI3) against methicillin-sensitive (MSSA) and methicillin-resistant (MRSA) S. aureus.
- To assess the safety and potential of FI3 as a therapeutic agent.
Main Methods:
- Purification of a fungal xenobiotic (FI3) with antimicrobial properties.
- Determination of minimum inhibitory concentration (MIC) against MSSA and MRSA.
- Assessment of cell viability and membrane integrity.
- Evaluation of biofilm disruption and synergistic effects with antibiotics.
- Toxicological assessment on mammalian tissue.
Main Results:
- FI3 demonstrated potent antimicrobial activity against MSSA (MIC: 32 µg/mL) and MRSA (MIC: 128 µg/mL).
- FI3 significantly reduced cell viability within 90 minutes by disrupting membrane homeostasis, with enhanced activity at pH 4.
- FI3 effectively inhibited biofilm adherence at 64 µg/mL and showed no toxicity to mammalian tissue.
- FI3 enhanced the potency of existing antibiotics.
Conclusions:
- FI3 exhibits significant antimicrobial and antibiofilm activity against S. aureus, including resistant strains.
- FI3 is safe for mammalian tissues and potentiates the efficacy of conventional antibiotics.
- FI3 represents a promising lead molecule for developing new treatments against bacterial infections.
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Microsporidia
Fungal Phylum Ascomycota
Fungal Phylum Basidiomycota
Measurement: Derived Units
Primary Active Transport

